The newly appointed CEO succeeds co-founder Shawn Regan, who steps into the chairman role.

Summary: Rhythmlink International has appointed Paul Buckman as CEO, succeeding co-founder Shawn Regan, who becomes chairman. Buckman’s background in medical devices will guide Rhythmlink in expanding its neurodiagnostic business. Regan will continue his involvement as a strategic advisor and investor.

Key Takeaways:

Paul Buckman has been appointed as the new CEO of Rhythmlink International, a company specializing in disposable neurodiagnostic devices.
Buckman replaces Shawn Regan, who co-founded Rhythmlink and has transitioned to the role of chairman of the board, continuing to offer strategic guidance and mentorship.
With over 30 years of experience in the medical device and life sciences sectors, including senior roles at St. Jude Medical and LivaNova PLC, Buckman is poised to lead Rhythmlink into its next phase of growth and innovation.

Rhythmlink International, a manufacturer of disposable neurodiagnostic devices including EEG electrodes, announced the appointment of Paul Buckman as its chief executive officer and member of the board of directors.

He will succeed Shawn Regan, co-founder of Rhythmlink, who has now assumed the role of chairman of the board. Regan will continue to provide strategic guidance and mentorship to the organization. In addition, he will continue to be an investor in the company.

“Regan’s unwavering commitment and leadership have been key to Rhythmlink’s growth and success over the past 22 years. His significant contributions during his tenure as co-founder and CEO have made a lasting impact on the culture of Rhythmlink as well as the neurodiagnostic industry,” according to a release from Rhythmlink.

Buckman brings over 30 years of experience in the medical device and life sciences sectors, including senior leadership roles at St. Jude Medical, Pathway Medical Technologies, and LivaNova PLC. Buckman’s history of success, coupled with his strategic vision and innovative approach, positions him to lead Rhythmlink to new levels of achievement, according to a release from the company.

“Under Paul’s guidance as CEO, we will continue to build upon our existing strengths in the ever-evolving neurodiagnostic space,” says Regan in a release. “The opportunities for Rhythmlink are numerous, and I’m excited to see our continued growth while we extend our focus and dedication to providing the highest level of customer service and improving patient care.”